QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: EU GVP Product- or Population-Specific Considerations I — Vaccines

Test your understanding of the concepts covered by GVP Product- or Population-Specific Considerations I: Vaccines.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A live attenuated vaccine is followed by a syndrome resembling disease caused by the wild-type pathogen. Which investigation is most appropriate?

Assume the syndrome is a vaccine reaction based solely on timing Investigate host factors, laboratory findings and other evidence that may distinguish vaccine-related disease-like illness from wild-type infection or another cause Exclude the event because live vaccines cannot produce disease-like syndromes Assess only whether the patient received another vaccine

Question 2 of 10 What should an organisation be able to demonstrate when documenting an important vaccine safety concern?

Only the final regulatory decision That all reported events were considered causal How the concern was identified, exposures and alternatives were assessed, evidence was integrated and the conclusion was reached That population-level evidence was used instead of individual case information

Question 3 of 10 Which issue can substantially weaken an observed-to-expected comparison?

The use of a clearly defined clinical outcome Differences in age, season, healthcare utilisation, disease incidence or case definition between the observed and expected populations The availability of vaccination dates The presence of a medically reviewed case series

Question 4 of 10 Which operational response best demonstrates preparedness for a rapid increase in vaccine reports?

Process cases in chronological order without triage Reduce medical review so that all cases can be closed quickly Plan intake, risk-based triage, processing resources, medical review, signal detection and escalation routes in advance Suspend reporting until the campaign ends

Question 5 of 10 When may experience with a similar vaccine appropriately inform the potential-risk assessment of another vaccine?

Whenever both products are vaccines, regardless of their characteristics Only when the products have identical trade names When scientifically relevant similarities exist, such as type, ingredients, target disease or biological mechanism, and the transfer is justified Never, because evidence from other vaccines is always irrelevant

Question 6 of 10 Which sequence best represents the conceptual vaccine pharmacovigilance lifecycle?

Communication, product withdrawal, reporting, exposure and retrospective assessment Exposure, safety information, individual and population assessment, signal prioritisation, benefit-risk evaluation, risk management and continued surveillance Clinical trial, authorisation, end of monitoring and routine use without reassessment Statistical signal, confirmed causality, product change and termination of surveillance

Question 7 of 10 Why can waning immunity be relevant to vaccine pharmacovigilance?

It changes the validity requirements for individual case safety reports It can alter breakthrough infections and the population context in which safety events are observed, linking effectiveness evidence with safety interpretation It proves that later adverse events are caused by booster doses It affects only manufacturing controls

Question 8 of 10 An incorrect route of administration causes a patient harm. How should this issue generally be conceptualised?

As evidence that the authorised vaccine product is intrinsically defective As an administration error that may generate safety information and require process, training or programme corrective action As an event that cannot be relevant to pharmacovigilance As proof that all administrations of the vaccine are unsafe

Question 9 of 10 How should vaccine benefit-risk assessment respond to a substantial change in disease incidence?

Safety standards should be lowered when disease incidence is high The vaccine's safety profile is automatically changed by disease prevalence The benefits and public-health consequences being weighed may change, while the underlying safety assessment standards remain applicable Disease incidence should not be considered because it is unrelated to pharmacovigilance

Question 10 of 10 Why is accurate vaccine lot or batch information particularly valuable during cluster investigation?

It proves that an event is vaccine-related It permits assessment of whether cases are concentrated around a particular product exposure and supports product-quality investigation It replaces the need to record the clinical event It is relevant only for vaccine effectiveness studies

QPPV.com

Knowledge Assessment: EU GVP Product- or Population-Specific Considerations I — Vaccines

Cookie Settings